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introDuction
Radiotherapy (RT) is an important treatment modality in 
the management of Central Nervous System (CNS) tumours 
for the optimization of tumour local control. Unlike other 
non-CNS malignancies, brain tumours have rarely a 
propensity for distant non-CNS metastases and consequen-
tially local control is key for the cure of these challenging 
malignancies. Recent advances in radiation techniques 
include the use of intensity- (IMRT) or volumetric- modu-
lated radiotherapy/arc therapy (VMAT), stereotactic radio-
surgery/fractionated RT (SRS/SFRT) and particle therapy 
(mostly protons and carbon ions). As a result of optimal 
dose conformation provided by the latter modality, parti-
cles can be used in a dose-escalation paradigm and/or 
for dose sparing of critical structures/organs at risks. The 
former could be applied to radio-resistant CNS tumours,1 
such as skull base chordoma and chondrosarcoma, or 
non-benign meningiomas2 and the latter in patients with 
a favorable prognosis, such as those with benign/low-grade 
brain tumours. For children, RT has been associated with a 
number of acute and late adverse events detailed later in this 
paper. Protons may decrease the rate of acute-3 and, more 
importantly, late toxicity4 usually seen with photon therapy 
and would thus increase substantially the therapeutic ratio 
of RT. The present paper details the most recent data for 
proton therapy delivered to patients with CNS tumours. 
Noteworthy, no data regarding carbon ions for CNS malig-
nancies will be summarized in this manuscript and we have 
included skull base tumors in this brain tumor review, as it 
is a major indication for protons. First, this paper will detail 
the rational of using protons for treating brain tumors. 
Second, an overview of the existing trials will be described 
and an attempt to discuss the limitations of such studies 
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Proton therapy (PT) has been administered for many 
years to a number of cancers, including brain tumours. 
Due to their remarkable physical properties, delivering 
their radiation to a very precise brain volume with no 
exit dose, protons are particularly appropriate for these 
tumours. The decrease of the brain integral dose may 
translate with a diminution of neuro-cognitive toxicity 
and increase of quality of life, particularly so in children. 
The brain tumour patient’s access to PT will be substan-
tially increased in the future, with many new facilities 
being planned or currently constructed in Europe, Asia 
and the United States. Although approximately 150’000 
patients have been treated with PT, no level I evidence 
has been demonstrated for this treatment. As such, it 
is this necessary to generate high-quality data and 
some new prospective trials will include protons or will 
be activated to compare photons to protons in a rand-
omized design. PT comes however with an additional 
cost factor that may contribute to the ever-growing 
health’s expenditure allocated to cancer management. 
These additional costs and financial toxicity will have to 
be analysed in the light of a more conformal radiation 
delivery, non-target brain irradiation and lack of poten-
tial for dose escalation when compared to photons. The 
latter is due to the radiosensitivity of organs at risk in 
vicinity of the brain tumour, that photons cannot spare 
optimally. Consequentially, radiation-induced toxicities 
and tumour recurrences, which are cost-intensive, may 
decrease with PT resulting in an optimized photon/
proton financial ratio in the end.
advances in knowledge: This review details the indica-
tion of brain tumors for proton therapy and give a list of 
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in adults and children alike will be provided and each section 
will finish with statements pertaining to the informed analysis. 
Finally, the additional costs and potential financial toxicity for 
patients of protons will be discussed at the end of this paper.
Proton beam therapy for brain tumours
This section elaborates on the physical rationale and dosimetric 
evidence for PT. Dose distribution in PT is characterized by a 
well-defined maximum range, which is a function of the initial 
energy, and a sharply defined Bragg Peak, where the bulk of the 
dose is deposited.5 Beyond the Bragg Peak, the dose drops to 
zero within a few millimetres. Compared to photons, this dose 
deposition results in a superior dose conformality and lower total 
integral dose delivered to surrounding tissue. This remarkable 
dose-profile is even more pronounced for Intensity Modulated 
PT (IMPT) available for Pencil Beam Scanning (PBS) systems, 
which can achieve particularly steep dose gradients.6 CNS 
tumours are inevitable in vicinity to many critical organs at risk 
(OARs),7 making them an especially relevant indication for PT. 
This rationale is supported by clear evidence for a dose-response 
relationship for many radiation-induced toxicities seen after RT 
for brain tumours. As an example, dose to the hypothalamus and 
pituitary correlates with the degree of endocrine dysfunction,8 
and dose to the hippocampus correlates with memory outcomes.9
The dosimetric advantage of PT compared to photons is undis-
puted, but the magnitude of clinical benefit is unknown. This 
benefit may substantially differ from individual cases to cases 
and is to a large degree dependent on tumor location. Adeberg et 
al10 evaluated the relative benefit of protons for five typical brain 
tumor locations and suggested that in general parietal tumours 
seem to benefit the most in terms of brain sparing. An exemplary 
Figure 1. Sagittal, axial and coronal views of proton dose distribution for a parieto-frontal tumor. PTV is shown in yellow. Figure 1b. 
Sagittal view of proton dose distribution for craniospinal irradiation. PTV is shown in yellow. Noteworthy, the color wash dose level 
display all dose levels. As such, absence of colors equals to absence of dose.
Figure 2. Supratentorial meningioma case. Doses as % of the prescribed dose and minimum dose level set at 20%. (a) IMRT dose 
distribution; (b) PBS dose distribution; (c) DVHs for homolateral (red) and controlateral (green) hippocampus. VOIs represented 
are PTV, brainstem, optic nerves and contralateral hippocampus. Infratentorial ependymoma case. Doses as absolute (GyRBE), 
minimum dose level set at 15GyRBE. (e) IMRT dose distribution; (f) PBS dose distribution; (g) DVHs for both cochleas (red and 
green). VOIs represented are PTV and both cochleas.
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PT dose distribution for a parieto-frontal located brain tumor 
is shown in Figure  1a. Even for very complex target volumes 
(Figure 2) involving large parts of the brain, such in whole-ven-
tricular RT for intracranial germ cell tumours, a dosimetric 
comparison study showed an approximately one-third reduction 
in integral dose to the brain, and also a better sparing of the circle 
of Willis with PT.11 This may be clinically significant, as radiation 
dose delivered to the circle of Willis was recently proposed as the 
best predictor of stroke in childhood brain cancer survivors.12 
Moreover the dosimetric advantage is particularly striking for 
large target volumes, such in the case of craniospinal irradia-
tion (CSI), where PT is able to completely spare OARs anterior 
to the vertebrae, as it is demonstrated in Figure 1b. Compared 
with modern photon techniques, PT obtained the lowest mean 
doses for OARs in CSI, with dose reductions of >10.0 Gy for 
parotid glands, thyroid and pancreas.13 Figure  2 details the 
decrease of dose delivered with PT as opposed to IMRT to the 
hippocampus and cochleas’ for a supra- and infratentorial tumor, 
respectively. Tamura et al14 estimated by in silico modelling that 
the use of PT instead of photons may result in a decrease in the 
lifetime attributable risk of radiation-induced secondary cancer 
after CSI. Although these results of in silico modelling have 
been confirmed by a previous study,15 caution should be taken 
not to over interpret these data stemming from a modelling 
computational paradigm, which do not represent ‘real-life’ data. 
Preliminary evidence suggests that this PT dosimetric gain also 
translates into a clinical benefit such as, for example, reduced 
neuro-cognitive disability16 and improved quality of life.17
The superior dose conformality of PT (Figure  2) has also 
however its dose-delivery hazards, in terms of increased sensi-
tivity to range and setup uncertainties, particularly so for IMPT. 
Robust planning18 and robust optimization19 can help to miti-
gate these dosimetric uncertainties. Another concern is the 
clinically use of a constant value of 1.1 for the relative biological 
effectiveness (RBE) for PT planning, whereas it is well known 
that RBE increases with increasing linear energy transfer (LET), 
thus presenting the highest value in the distal fall-off.20 Other 
factors, not limited but including total dose, fractional dose, 
biological endpoint, oxygenation and tissue or cell type (char-
acterized normally by α/β) have an influence on RBE.20,21 LET/
RBE evaluation and LET optimization of PT plans can avoid high 
LET areas, and therefore unintended increase in biological dose, 
in critical structures such as the brainstem22 or periventricular 
area23 where the brain stem-cells are located. There is a concern 
within the community that high-LET values at the distal range 
of the beam may cause toxicities be it radiological24 or clinical.25 
For example, adjusting treatment field angles for posterior fossa 
tumours can substantially reduce LET values in this OAR.26 
Future developments in these and other areas are likely to only 
enhance the benefits of PT even further.
Establishing the role of proton therapy for the 
management of brain tumours: clinical trials
In the era of evidence-base medicine (EBM), high quality of 
data27 is needed to justify the additional cost factor associated 
with proton therapy for brain and non-CNS tumours alike. 
Although some authors have challenged the hierarchal evidence 
paradigm in EBM,28 it remains that randomised controlled trials 
(RCTs), representing the so-called level I evidence, are of para-
mount importance in the assessment of the ‘value’ of any treat-
ment modality in cancer care. The ethical issues of such RCTs for 
proton therapy have been long debated and are not the focus of 
this section.29 Clinical validation of proton therapy can also be 
achieved with a non-RCT paradigm: specifically, a model-based 
driven validation approach, with an enrichment of the experi-
mental arm.30 It is foreseeable that a combination of these trial 
strategies will best generate data that will create scientifically 
sound evidence on how best to select patients for protons and 
increase the therapeutic balance of a number of malignancies, 
including CNS tumours for value-based cancer management. 
Caution however should be stressed that, depending on the 
selected study endpoint, such as late toxicity including but not 
limited to radiation-induced tumours, the event can be observed 
after a long interval after PT. As such, the follow-up time of 
studies should be consequentially sufficient, which creates a 
significant challenges for prospective trials, one of which is the 
trial funding that should be appropriate to fund an extended 
period of follow-up.
A number of RCTs and prospective Phase II trials have been 
proposed and are currently accruing patients worldwide. Exclu-
sion criteria of the majority of trials are previous radiation to the 
head and neck or brain and very extensive lesions, which would 
have been previously defined as gliomatosis cerebri. Several 
databases were queried ( clinicaltrials. gov, CTSU/NRG, EORTC, 
PTCOG) and 43 prospective brain tumour trials activated 
between 1996 and 2019 were identified. Trials that assessed the 
value of targeted agent/immune checkpoint inhibitors or hypoxic 
target agents with RT including protons were excluded. Median 
accrual target of these trials was 80 patients, ranging from 12 to 
625. Only a minority (n = 3; 7%) of trials had no age limit. Most 
trials were for adults (n = 23; 53%) or pediatric (n = 12; 30%) 
patients. Three (7%) studies were for children and adolescent 
and young adults. Interestingly, a substantial number of studies 
(n = 9; 21%) were for all brain tumours. The most common brain 
tumours for these trials were chordoma or chondrosarcoma (n 
= 7; 16%), meningioma (n = 6; 14%) and low-grade glioma (n 
= 6; 14%). Most of the studies were however not accruing (n = 
17; 39%) or were in the process of activation (n = 2; 5%). Five 
(12%) studies were closed and 3 (7%) had an unknown status. 
The 16 (37%) remaining studies accruing patients in Europe and 
in the United States are detailed in Table 1. One of the low-grade 
glioma trials has been recently closed, achieving target-accrual. 
Noteworthy, WHO grade II glioma patients could be included 
in this trial from Boston, providing that progressive/recurrent 
disease was observed, neurological symptoms were uncontrolled 
and/or patient was aged >40 years or presented MIB-1 of ≥3%. 
Mean age of this cohort was 37.5 years (range, 22–56) and the 
gender male/female ratio was 1.9. 40% of the cohort have been 
followed at 5 year. The results will be published soon.
Table 1 displays also a number of tumour registries that are active 
in the United States, one of which is dedicated to children only. 
The target of total number of patient’s registration is over 28’000. 
In Europe, it is also foreseen to have a prospective data collection 
4 of 20 birpublications.org/bjr Br J Radiol;92:20190237
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of patients treated with protons in the framework of PARTICLE-
Care. This project is a joint collaboration of the European Organ-
isation for the Research and Treatment of Cancer (protocol: 
E2RADIatE, EORTC 1811) and the European Society for Radio-
therapy and Oncology. It is foreseen that the first patient will be 
included into this prospective database by the end of 2019.
Adult brain tumours
Patient with benign brain tumours and low-grade CNS tumours 
might show some clinical benefit from PT. A substantial number 
of Low Grade Glioma (LGG) patients are long-term survivors.31 
The negative impact of photon radiation therapy on cognition has 
been demonstrated.32 Plan comparative studies have shown the 
potential of proton therapy to decrease radiation dose delivered 
to OARs.33 Currently, there are no published data of random-
ized trials comparing protons with photons for these tumours 
(Table 1). Reported results however regarding long-term toxic-
ities from clinical proton studies show encouraging results,34–36 
although the patient numbers are small. More elucidation on the 
real benefit regarding the use of protons in treating LGGs can 
be expected from the results from the ongoing randomized trial.
Due to the poor prognosis of high-grade gliomas, a dose escala-
tion paradigm has been advocated for these challenging tumours. 
A study applying an escalated boost with protons to a total dose up 
to 90 Gy(RBE) lead to improvement in tumor control rate as well 
as median survival time.37 Nevertheless, the study enclosed only a 
small number of patients with no molecular analysis and a substan-
tial number of patients had to undergo surgery due to radiation 
brain necrosis.
Some of the meningiomas can also be considered low-grade 
benign tumours. Total surgical resection is the treatment of 
choice for symptomatic/progressive meningioma. However, not 
all meningioma are suitable for surgery and therefore radiation 
therapy is often indicated. In particular, patients with residual 
non-benign, recurrent or high-grade tumours are candidates 
for radiation therapy. Large and complex shaped meningioma 
located close to brainstem (Figure  2), optical nerve, pituitary 
gland and cochlea may present however a therapeutic challenge 
and proton may provide dose escalation possibilities for non-be-
nign meningiomas.2 Eight retrospective studies delivering PT 
were conducted across a number of countries including Switzer-
land, Germany, Sweden and USA.38–45 The sample size within 
the studies ranged from 39 to 170 participants (Table 2). Four 
studies included meningioma Grad 1–3,40,42,44,45 while two 
included Grade 1–239,41 and one Grade one meningioma only.43 
In two studies a combination of photons and carbon ions was 
given to patients with Grade 2–3 meningioma whereas patients 
with Grad one tumours received proton therapy only.42,45 
Five-year local control rates for low-risk meningioma were 
better (94–100%) when compared with high-risk meningioma 
(49–88%) and tumor grading was found to be of prognostic 
significance in univariate analysis in four studies.39,40,44,45 Proton 
therapy induced toxicity was moderate with a rate of 3.6–12.8% 
Grade ≥ 3 late effects. The results stemming from these small PT 
series are in line with modern photon series and cannot prove 
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In summary, it is unlikely that proton therapy delivered for 
high-grade brain tumors might translate into a substantial clin-
ical benefit for CNS-tumor patients. Protons could however be 
administered to low-grade (i.e. glioma) or benign (i.e. menin-
gioma) brain tumors, as these patients experience substantial 
long survival times, in order to possibly decrease the probability 
of long term toxicity. Alternatively, proton therapy could be 
administered to patients with non-benign meningioma with a 
dose-escalation paradigm.
skull-base tumours
Skull-base chondrosarcoma (sbChS) and chordoma (sbC) are 
very rare tumours with an incidence of <1 per million.46 They 
are usually in direct vicinity of OARs, including but not limited 
to the optic apparatus, brainstem, pituitary gland and cochleae 
and are considered radio-resistant.47,48 Local tumour control is 
associated with overall survival and is thus of paramount impor-
tance.49,50 SbChS and sbC are usually managed with cytoreduc-
tive surgery and postoperative radiotherapy. The importance of 
optimal surgery (i.e. optimizing the tumor geometry/debulking) 
with potentially sequential surgical procedures, before radio-
therapy has been advocated by many groups.50–54 The outcome 
of patients with sbChS/sbC treated with adjuvant or salvaged 
photon radiation therapy is not optimal. When gauging the 
benefit of protons for these skull-base tumours, it is important to 
acknowledge that, due to the rarity of this condition, only obser-
vational studies stemming usually from one institution, with few 
exceptions,50 have been published. Consequentially, no level I or 
II evidence have been proven on the superiority of protons over 
photon radiotherapy, although the outcome data published by 
non-particle radiotherapy is somewhat poor. Two photon series 
reporting on 17 and 48 sbC and extra cranial chordomas patients 
have shown that delivering a median dose of 50 Gy with conven-
tional radiotherapy resulted in a 5 year PFS and 5 year LC of 17 
and 23%, respectively.55,56 As such, conventional radiotherapy 
may provide valuable palliation for these challenging patients 
but chordomas are rarely cured with this therapeutic modality. 
It has been claimed that historical photon series, such as those 
reported above, do not reflect the accurate efficiency of modern 
photon radiotherapy series. A recent study from the UCLA group 
reported on 57 sbC patients treated with a median dose of 17.8 
and 63.4 Gy delivered with SRS and SFRT, respectively.57 The 
observed 5 year PFS for the entire cohort was only 35.2%. Of note, 
SRS and SFRT produced comparable rates of tumour control. 
Numerous modern SRS and SFRT series have shown suboptimal 
outcomes for sbC patients treated with these radiation modali-
ties.57–59 These suboptimal results may be best explained by the 
stereotactic margins defined during the planning process and 
radiation dose delivered to these patients. Regarding the former, 
Snider et al have shown undisputedly the importance of margins 
for extracranial chordomas.60 The seminal paper by Pearlman et 
al have shown a dose-response for chordomas.47 More recently, 
a South Korean study reported on 35 sbC patients treated with 
a median 75.5 EQD2 delivered by proton therapy. The observed 
5 year local tumour control was 92.8 and 63.0% for patients 
treated with ≥69.6 and<69.6 Gy, respectively.61 Likewise, an anal-
ysis of 863 chordoma patients captured in the National Cancer 
Data base has shown undisputedly that dose for chordoma was 
associated with a significant increase in OS on univariate anal-
ysis.1 Other proton series have shown such a dose-response with 
sbC.62 This dose-response relationship has also been observed 
with photons55,63 : in the above-referred US series, higher dose 
of SFRT was associated with a significant higher rate (p = 0.013) 
of tumour local control.57 As such, high-dose radiation therapy, 
with non-stereotactic margins, have to be delivered to chor-
doma patients postoperatively. Table 3 details the outcome and 
prognostic factors of sbChS and sbC adult patients treated with 
proton therapy, mostly delivered with a passive scattering para-
digm. Noteworthy, the prognostic impact of gender is unproven, 
as all but two series with contradictory results,64,70 have shown 
that chordoma is gender-neutral. Tumour volume before proton 
therapy, with various cut-offs ranging from 20 to 70 cc, is a major 
prognosticator. Interestingly, the outcome of sbC and scChSa 
patients have improved substantially in recent years (Table  3). 
Finally, delivering high dose proton radiation to the skull base 
tumours may induce toxicity,52,65–69,71–74 including but not 
limited to the brainstem. At the Paul Scherrer Institute, we have 
seen no brainstem radiation toxicity in adult skull-base tumour 
patients treated with protons. Debus et al reported on 367 skull 
base tumours patients treated in Boston with combined proton/
photon radiotherapy.49 Brainstem toxicity was observed in 4.6% 
of cases and the estimated toxicity-free survival was 88%.
Protons should thus be the standard of care for sbC or sbChSa, as 
a dose escalation can be achieved with this treatment modality, 
maximizing the chances of cure for these challenging patients.
Pediatric brain tumours
Cancer affects more than 380’000 children aged 0–19 every year 
globally75 and is the leading cause of childhood death by disease 
in high-income countries (HIC). Nevertheless, cancer cure rates 
in HIC currently are near 80% and are on the rise thanks to new 
advances in medical treatments This leaves many childhood 
cancer survivors (CCS) with a potentially normal lifespan, during 
which maintaining both good health status and quality of life is 
of paramount importance.76 Treatment-related toxicity brings 
a significant morbidity burden on CCS, most of all for patients 
with primary brain cancers.77 Reasons for this are an increased 
sensitivity due to ongoing tissue growth and neuro-cognitive 
development, smaller anatomic dimensions bringing critical 
organs closer to treatment areas and a longer lifespan left to 
develop side-effects. The most significant toxicities associated 
with brain tumor irradiation are vascular complications such as 
radiation necrosis (RN) and Moya-Moya syndrome, impairment 
of neurocognitive development, including loss of IQ scores, 
visual, hearing or endocrine deficits as well as skin changes 
such as alopecia. In the case of CSI (Figure 1b), neck, thoracic, 
abdominal and pelvic organs can develop late sequelae of radi-
ation therapy. As an example, vertebral body irradiation leads 
to decrease of adult height78–80 with a reported incidence rate 
of 3–26%.81 RN can result in numerous symptoms or deficits, 
depending on its location, such as seizures or motor impairment. 
Seven papers reported on RN induced by proton therapy in pedi-
atric patients (Table 4). Sample sizes ranged between 17 and 313 
patients, with ages between 19 months and 10 years. Time to 
RN ranged between 3 and 9 months. Median PT doses of 54 Gy 
12 of 20 birpublications.org/bjr Br J Radiol;92:20190237
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RBE were used across all seven studies. Grade 3–4 RN ranged 
between 2 and 3.6% at 5 years.82–88 PT has demonstrated its 
ability to better spare uninvolved normal tissues including crit-
ical OARs compared to standard photon therapy. It has therefore 
become a widely accepted radiation modality for several child-
hood malignancies. Advantages of PT for the irradiation of brain 
tumours reside in a better sparing of healthy brain tissue and 
other OARs (Figure 2), not limited but including the cochlea, the 
pituitary gland, the hippocampus, the optic structures and the 
brainstem.89 For the spinal cord, posterior proton field arrange-
ments (Figure  1b) allow for an excellent sparing of all organs 
anterior to the vertebral bodies as described above.90 Pediatric 
brain tumours, for which PT has been most commonly used, 
are craniopharyngiomas,91 ependymomas (Figure  2),92 germ 
cell tumours,93 low-grade gliomas,94 medulloblastomas and 
atypical teratoid/rhabdoid tumours (ATRT)95,96 (Table 5). Four 
retrospective studies, published with exclusively ependymoma 
patients, reported OS and PFS rates ranging from 84–100% to 
76–80%.92,97–99 In medulloblastoma studies,100,102,103 sample 
sizes ranged between 15 and 59 patients, with ages between 2.9 
and 6.6 years. The context of re-irradiation also makes a partic-
ularly strong case for the use of very conformal RT modalities 
such as PT, as treatment of recurrences can still lead to cure in 
some instances, such as for localized ependymoma relapses.101
The administration of protons to children with brain tumors 
represent an unique opportunity to decrease the likelihood of 
late CNS toxicity by decreasing the integral dose to the brain, 
especially so in very young patients with tumors such as ATRTs, 
ependymomas or medulloblastomas.
Costs considerations/financial toxicity
Across HICs, cancer management costs are escalating, driven 
mainly by consumerism in health care, the demographic transi-
tion of a growing elderly population and by the delivery of costly 
new therapies. Although there is an association between high-
spending health care systems and lower cancer mortality,104 it is 
questionable if the growth in cancer spending is sustainable in 
the long-time in high-income countries.
Proton therapy is an expensive anti cancer treatment, with a cost 
factor of approximately 2.5, when compared to modern RT tech-
niques.105 This is certainly due to the considerable investment 
costs but also due to the high operation and maintenance costs. 
Ongoing technical developments may lead to cost reduction but 
it is not expected that a dramatic decrease in costs will be reached 
in the near future.106 As a result, there is an ongoing debate on 
the value of proton therapy and its cost-effectiveness (CE).107,108
As care for medical conditions, such as cancer, usually involves 
multiple disciplines and numerous interventions at different time-
points, the true value cannot be determined by simply comparing 
costs of two treatment modalities. Consequently, CE analysis must 
also consider patient`s longtime outcome, toxicity and quality of 
life by tracking patient outcomes and costs longitudinally.109
Four publications on CE of proton therapy in brain tumours 
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used Markov modelling110,112,113 and Monte Carlo simulations111 
to compare proton vs photon therapy. All investigators have 
shown that proton therapy is cost-effective with regard to long-
term risk of radiation side-effects. Three studies even demon-
strated a cost saving effect of proton therapy.
These analyses are based on theoretical modelling concepts using 
assumptions, which remain questionable. Empirical comparative 
data establishing the clinical advantages and health economic 
appropriateness of proton compared to photon therapy is lacking 
but urgently needed. It is foreseen that costing data will be 
captured in the EORTC 1811 protocol/ParticleCare.
Most insurances reimburse the costs of proton therapy for brain 
tumours listed in this manuscript. Nevertheless, patients may 
experience expenses to cover costs for housing and traveling 
during 6–7 weeks treatment, special food and potentially lose 
wages. For some patients, these out of pocket payments can cause 
substantial financial distress that adversely affects a patient’s 
quality of life, treatment choice, treatment compliance, and 
treatment outcome.114 Treatment related financial distress can 
be just as toxic as the effects of chemotherapy or radiation and 
was therefore defined as a treatment related financial toxicity.115 
Approximately 16% of patients undergoing proton therapy for 
brain tumours in Switzerland experience moderate to severe 
financial distress (unpublished own data). However, very limited 
evidence is available about the incidence of financial toxicity, its 
associated morbidity and its preventability in proton therapy.
conclusions
The dose deposition advantage of PT for the treatment of brain 
tumours are instantly apparent when planning comparisons of 
proton vs photon are made. Evidence for PT in adult benign and 
low-grade tumours is however limited on retrospective analyses. 
The available data suggests that proton therapy achieves good local 
control in some high-grade tumours with acceptable toxicity and 
that the toxicity profile for low-grade tumours warrants prospec-
tive analyses. For skull-base, radio-resistant tumours, high-dose 
(i.e. >70 GyRBE) proton therapy, with non-stereotactic margins, 
have to be delivered to patients postoperatively. Delivering protons 
to children with brain tumours may increase the therapeutic ratio. 
In the era of EBM, high-quality data needs to be rapidly generated 
to justify the higher costing of this radiation modality, which can 
have substantial financial toxicity to the patients and their families.
Table 6. Cost-effectiveness studies for proton vs photon therapy of brain tumors
Author 













Risk of hearing loss,
IQ loss, GHD, 
hypothyroidism, 
osteoporosis, cardiac 
disease, fatal and nonfatal 
SMN
Gain of QUALY of 0.68 per patient;
Estimated cost difference (protons 
vs photons) per patient
−23,646.5 EUR













Risk of GHD, hearing 
loss, hypothyroidism, 





Gain of QUALY of 3.46;
Total difference in costs (protons vs 
photons): - 32,579.1 Dollar











Risk of hearing loss due 
to cochlear dose for three 
different QoL measures 
(EQ-5D, HUI3, SF-6D)
Gain of QUALY between 0.98 and 
1.82 and ICER of 11,773 and 21,716 






2015 Pediatric CNS 
tumors
Comparison 
of PBT vs 





Risk of GHD Hypothalamic proton doses 
between 5 and 25 Gy can be cost-
effective, between 5 and 20 Gy even 
cost saving in some scenarios
ACTH, adrenocorticotropic hormone; GHD, growth hormone deficiency; ICER, incremental cost-effectiveness ratio; IMRT, intensity modulated 
radiation therapy; IQ, intelligence quotient; PBT, proton beam therapy; QoL, quality of life; QUALY, quality adjusted life years; RT, radiation 
therapy; SMN, secondary malignant neoplasm.
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